Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease

Movement Disorders

Volumn 24, Issue 6, 2009, Pages 932-936

  Henley, Susie M D ^a   Wild, Edward J ^a   Hobbs, Nicola Z ^a   Frost, Chris ^a,b   MacManus, David G ^a   Barker, Roger A ^c   Fox, Nick C ^a,d   Tabrizi, Sarah J ^a,d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

CAG repeat length; Huntington's disease; Longitudinal; MRI

Indexed keywords

ADULT; ARTICLE; BRAIN ATROPHY; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; FEMALE; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; RELIABILITY; SCORING SYSTEM; UNIFIED PARKINSON DISEASE RATING SCALE;

ADULT; ATROPHY; BRAIN; BRAIN MAPPING; DISEASE PROGRESSION; HUMANS; HUNTINGTON DISEASE; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 67651162162     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22485     Document Type: Article

References (24)

1. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983.
2. Craufurd D, Snowden J. Neuropsychological and neuropsychiatric aspects of Huntington's disease. In: Bates G, Harper P, Jones L, editors. Huntington's disease, 3rd ed. Oxford: Oxford University Press; 2002. p 62-94.
3. Gutenkst C, Norflus F, Hersch SM. The neuropathology of Huntington's disease. In: Bates G, Harper P, Jones L, editors. Huntington's disease, 3rd ed. Oxford: Oxford University Press; 2002. p 251-275.
4. Fennema-Notestine C, Archibald SL, Jacobson MW, et al. In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease. Neurology 2004;63:989-995.
5. Ruocco HH, Bonilha L, Li LM, et al. Longitudinal analysis of regional gray matter loss in Huntington disease: effects of the length of the CAG repeat. J Neurol Neurosurg Psychiatry 2007;79:130-135.
6. Kassubek J, Bernhard LG, Ecker D, et al. Global cerebral atrophy in early stages of Huntington's disease: quantitative MRI study. Neuroreport 2004;15:363-365.
7. Rosas HD, Liu AK, Hersch S, et al. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurol 2002;58:695-701.
8. Rosas HD, Hevelone ND, Zaleta AK, et al. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 2005;65:745-747.
9. Rosas HD, Salat DH, Lee SY, et al. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain 2008;131:1057-1068.
10. Fox NC, Freeborough PA. Brain atrophy progression measured from registered serial MRI: validation and application to Alzheimer's disease. J Magn Reson Imaging 1997;7:1069-1075.
11. Henley SM, Frost C, MacManus DG, et al. Increased rate of whole-brain atrophy over 6 months in early Huntington disease. Neurology 2006;67:694-696.
12. Shoulson I, Fahn S. Huntington disease: clinical care and evaluation. Neurology 1979;29:1-3.
13. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord 1996;11:136-142.
14. Freeborough PA, Fox NC, Kitney RI. Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. Comput Methods Programs Biomed 1997;53:15-25.
15. Woods RP, Grafton ST, Holmes CJ, et al. Automated image registration. I. General methods and intrasubject, intramodality validation. J Comput Assist Tomogr 1998;22:139-152.
16. Paulsen JS, Hayden M, Stout JC, et al. Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol 2006;63:883-890.
17. Solomon AC, Stout JC, Johnson SA, et al. Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia 2007;45:1767-1776.
18. Langbehn DR, Brinkman RR, Falush D, et al. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 2004;65:267-277.
19. Marder K, Zhao H, Myers RH, et al. Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology 2000; 54:452-458.
20. Witjes-Ane MN, Mertens B, van Vugt JP, et al. Longitudinal evaluation of "presymptomatic" carriers of Huntington's disease. J Neuropsychiatry Clin Neurosci 2007;19:310-317.
21. Aylward EH, Rosenblatt A, Field K, et al. Caudate volume as an outcome measure in clinical trials for Huntington's disease: a pilot study. Brain Res Bull 2003;62:137-141.
22. Paulsen JS, Magnotta VA, Mikos AE, et al. Brain structure in preclinical Huntington's disease. Biol Psychiatry 2006;59: 57-63.
23. Rosenblatt A, Liang KY, Zhou H, et al. The association of CAG repeat length with clinical progression in Huntington disease. Neurology 2006;66:1016-1020.
24. Fox NC, Cousens S, Scahill R, et al. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects [see comments]. Arch Neurol 2000;57: 339-344.